Harper M E, Wilson D W, Jensen H M, Pierrepoint C G, Griffiths K
Tenovus Institute for Cancer Research, University of Wales College of Medicine, Heath Park, Cardiff.
J Steroid Biochem. 1987;27(1-3):521-4. doi: 10.1016/0022-4731(87)90349-9.
Survival of patients who received endocrine therapy as first-line treatment for their prostatic cancer was statistically analysed in relation to several parameters, primary tumour stage, metastatic status, age, pretreatment plasma hormone concentrations and Gleason grade. Prognostic indices were derived for both M0 and M1 patients in which Gleason grade and plasma testosterone concentrations were significant prognostic factors. In the M1 patients growth hormone values were also significant and to a lesser degree age. The relationship of Gleason grade to testosterone, growth hormone, prolactin, the gonadotrophins and age was also analysed. No significant differences in any of these hormones was noted with increasing Gleason grade but the age of patients with Grade 5 tumours was significantly lower.
对接受内分泌治疗作为前列腺癌一线治疗的患者的生存情况，就几个参数进行了统计学分析，这些参数包括原发肿瘤分期、转移状态、年龄、治疗前血浆激素浓度和 Gleason 分级。得出了 M0 和 M1 患者的预后指标，其中 Gleason 分级和血浆睾酮浓度是显著的预后因素。在 M1 患者中，生长激素值也具有显著意义，年龄的影响程度较小。还分析了 Gleason 分级与睾酮、生长激素、催乳素、促性腺激素及年龄之间的关系。随着 Gleason 分级增加，未发现这些激素中有任何显著差异，但 5 级肿瘤患者的年龄显著更低。
